1. Rituximab immunotherapy: it’s getting personal
by Mitch A. Phelps
Blood
Volume 129(19):
May 11, 2017
©2017 by American Society of Hematology

2. Observed relationship between rituximab pharmacokinetic parameters, (A) rituximab elimination half-life (T1/2β) and (B) area under the concentration-time curve (AUC1), relative to TMTV0.
Observed relationship between rituximab pharmacokinetic parameters, (A) rituximab elimination half-life (T1/2β) and (B) area under the concentration-time curve (AUC1), relative to TMTV0. See Figure 2 in the article by Tout et al that begins on page 2616.
Mitch A. Phelps Blood 2017;129:
©2017 by American Society of Hematology